BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For
information on access to our products, please call our customer service line at 1-800-469-0261.
BDSI®'s website may contain proprietary notices and copyright information, the terms of which must be observed and followed. Information on this website may contain technical inaccuracies or typographical errors. Information may be changed or updated without notice.
YOU ASSUME ALL RESPONSIBILITY AND RISK FOR THE USE OF BDSI®'s WEBSITE AND THE INTERNET GENERALLY. THIS WEBSITE IS PROVIDED BY BDSI ON AN "AS IS" BASIS. BDSI® MAKES NO AND DISCLAIMS ALL REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, LEGAL OR EQUITABLE, AS TO YOUR USE OF THIS WEBSITE, THE OPERATION OF THIS WEBSITE, OR THE INFORMATION, CONTENT, OR MATERIALS INCLUDED ON OR LINKED TO THIS WEBSITE. TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, BDSI® DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OR OTHER PROPRIETARY RIGHTS, AND FREEDOM FROM ERRORS, VIRUSES, BUGS, OR OTHER HARMFUL COMPONENTS. BDSI® WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS WEBSITE, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OR DAMAGES RESULTING FROM LOSS OF USE, DATA, OR PROFITS, OR BUSINESS INTERRUPTION ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE USE OF THIS WEBSITE, ANY DELAYS ON THIS WEBSITE, OR THE INABILITY TO USE THIS WEBSITE, ANY PORTION THEREOF, OR ANY HYPERLINKED WEBSITE, WHETHER BASED ON CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, EVEN IF BDSI® HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
BDSI® has made a conscientious effort to display and describe information about BDSI on the site accurately so that you can get a good idea of our business. However, the materials on this website are for your general educational information only. BDSI® does not practice medicine or provide medical services or advice, and the information on this website should not be considered medical advice. You should always rely on your healthcare professional for diagnosis and treatment.
Product information contained on this website is intended for residents of the United States unless otherwise specified.
BDSI®'s website may contain links to other websites. BDSI® is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by BDSI® of the linked website or any association with its operators. BDSI® makes no representations whatsoever about any other site you may access through www.bdsi.com. Any concerns regarding any product or service offered by a website to which the BDSI® website is linked or the link itself should be directed to the operator of that specific website and not to BDSI®. If you use these links, you are leaving this website. BDSI® has not reviewed all of these third-party sites and does not have control over, and is in no manner responsible or liable for, the availability and content of the websites to which BDSI®'s website is or may be linked. BDSI® makes no representations whatsoever about any other website you may access through www.bdsi.com and disclaims all liability with regard to your access to such linked websites. If you access any of the third-party sites linked to this website, you do so at your own risk.
Unless otherwise set forth in a written agreement between you and BDSI®, you must adhere to BDSI®'s linking policy as follows: (i) any link to BDSI®'s website must be a text-only link clearly marked "BioDelivery Sciences International website," (ii) the appearance, position, and other aspects of the link may not be such as to damage or dilute the goodwill associated with BDSI®'s name and trademarks, (iii) the link must point to the following URL listed below: www.bdsi.com and not to other pages within our website, (iv) the appearance, position, and other attributes of the link may not create the false appearance that your organization or entity is sponsored by, affiliated with, or associated with BDSI®, and (v) BDSI® reserves the right to revoke its consent to the link at any time and in its sole discretion.
We do not intend to collect any personally identifiable information from children through our website. Please do not allow children under the age of 13 to provide any personally identifiable information related to our website.
All software and content included on this site, such as text, graphics, logos, button icons, images, audio clips, and software, is the owned or licensed property of BDSI® or its software and content suppliers and protected by US and international copyright laws. The compilation (meaning the collection, arrangement, and assembly) of all content on this site is the exclusive property of BDSI® and protected by US and international copyright laws. BDSI® grants you permission to view and use content and software made available to you on the site in connection with your use of the site. Any other use, including the reproduction, modification, distribution, transmission, republication, display, or performance, of the content and software on this site is strictly prohibited.
BDSI®'s names and logos referenced on the website are trademarks of BDSI® in the United States and other countries and may not be used in connection with any product or service in any manner that is likely to cause confusion among customers or in any manner that disparages or discredits BDSI®.
All other trademarks not owned by BDSI® that appear on this website are the property of their respective owners, who may or may not be affiliated with, connected to, or sponsored by BDSI®.
The content of this website contains certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties, including those detailed in BDSI®'s filings with the Securities and Exchange Commission.
Forward-looking statements may include, without limitation, statements regarding BDSI®'s plans, objectives, projections, expectations, and intentions, and other statements identified by words such as "projects,” "may,” "could,” "would,” "should,” "believes,” "expects,” "anticipates,” "estimates,” "intends,” "plans," or similar expressions. These statements are based upon the current beliefs and expectations of BDSI®'s management; however, actual results, including, without limitation, actual sales results, if any, or the timing for completion and results of scheduled or additional clinical trials and FDA review of BDSI®'s formulations and products, may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve risks and uncertainties that are subject to change based on various factors (many of which are beyond BDSI®'s control).
Peak sales and market size estimates provided on this site and otherwise by BDSI® have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all.
BDSI® disclaims any intent or obligation to update its forward-looking statements.
Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potentialRead more
RALEIGH, N.C. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief FinancialRead more
RALEIGH, N.C. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open ofRead more